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Abstract Irreversible conversion of xanthine dehydrogenase
(XDH) to its oxygen free radical producing oxidase (XO) form
occurs through an uncharacterized proteolytic process, which was
studied in human liver. Upon incubation of fresh unfrozen liver
cytosol, XDH remained intact. When recombinant human XDH
was coincubated with subcellular fractions of human liver, the
mitochondrial intermembrane space was shown to contain a heat-
labile activity that converted XDH irreversibly to XO. This
activity is resistant to inhibitors of all major groups of proteases.
We postulate that this novel type of proteolytic enzyme is
released into the cytosol upon mitochondrial damage.
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1. Introduction
Xanthine dehydrogenase/oxidase (EC 1.1.1.204/1.2.3.22)
catalyzes the last two steps of purine catabolism in man, for-
mation of the end product uric acid from hypoxanthine and
xanthine. The mammalian enzyme is synthesized as a dehy-
drogenase (XDH), which uses NAD as the electron acceptor,
but it can be converted into an oxidase (XO) both in vivo and
in vitro. The oxidase form uses molecular oxygen as the elec-
tron acceptor and releases substantial amounts of superoxide
anions (Oc32 ) and hydrogen peroxide (H2O2) under appropri-
ate conditions, e.g. during tissue reperfusion following ische-
mia, thus potentially contributing to tissue injury (for reviews,
see [1,2]).
Xanthine dehydrogenase is a homodimer with a subunit
molecular mass of approximately 150 kDa. Conversion into
xanthine oxidase (XO) may occur through sulfhydryl group
oxidation, which can be reversed with thiol reagents, e.g. di-
thiothreitol (DTT) [3]. Reversible XDH-XO conversion has
been attained experimentally by glutathione depletion [4], is-
chemia [5^7], ischemia-reperfusion and oxidizing agents, such
as hydrogen peroxide [8].
Irreversible conversion occurs during puri¢cation proce-
dures, unless the tissue samples to be analyzed are prepared
rapidly and with a minimum of manipulation prior to meas-
uring the activities [9]. Even if such precautions are taken,
tissue preparations consistently contain a minimum of 10^
15% of total XDH+XO activity in the oxidase form [5].
A model for the XDH tertiary structure has been proposed
[10,11]. According to this model, the 150 kDa subunit consists
of three relatively protease-resistant globular domains with
approximate molecular masses of 20, 36^40 and 85^92 kDa,
held together by protease-sensitive peptide ‘hinges’. Proteoly-
sis at these sites can be attained in vitro by partial digestion
with a variety of proteases, including trypsin, K-chymotrypsin,
thermolysin and subtilisin [9^12]. The observation that the
proteolytically modi¢ed XDH comigrates with the non-di-
gested native polypeptide in non-reducing gels and gel ¢ltra-
tion experiments suggests that these domains remain associ-
ated with each other despite limited proteolysis [11]. When the
modi¢ed peptide is run on a denaturing gel, the fragments
dissociate giving rise to three bands of the above-mentioned
sizes.
Proteolytic processing of XDH during tissue ischemia takes
place through cleavage of an approximately 15^20 kDa frag-
ment from each subunit [13,14], and is believed to occur sub-
sequent to the reversible conversion [5,6]. The proteolytic con-
version has been hypothesized to be modulated by
intracellular calcium levels [5,15], though apparently not
through a calcium-dependent protease (calpain) [16]. Calci-
um-dependent proteolytic XDH-XO conversion has been
shown to be sensitive to calmodulin inhibitors [17,18], but
the enzyme responsible for the conversion is unknown.
In this study, we demonstrate a proteolytic activity found in
human liver that converts XDH irreversibly to XO. This solu-
ble activity has been localized to the mitochondrial intermem-
brane space and is resistant to conventional antiproteases.
2. Materials and methods
2.1. Human liver tissue samples
Fresh human liver samples were obtained from partial orthotopic
liver transplantations at the Hospital for Children and Adolescents,
University of Helsinki. The donor livers had been perfused with and
preserved in ice-cold University of Wisconsin solution for up to 4 h
prior to tissue homogenization. The liver samples were obtained after
approval of the local ethical committee and guidelines for discarded
human tissue were followed.
Mitochondria were puri¢ed from fresh liver tissue as described be-
low. Warm ischemia/hypoxia was simulated by incubating 9100 mg
tissue pieces under 50 mM potassium phosphate bu¡er (pH 7.8) at
37‡C for up to 2 h.
2.2. Puri¢cation and sequencing of XDH cleavage products
Xanthine oxidase was puri¢ed from human milk as described [19],
and from human liver using an immunoa⁄nity column with rabbit
polyclonal anti-XO antiserum coupled to Sepharose [19]. The puri¢ed
enzyme preparations were electrophoresed on a 5% denaturing poly-
acrylamide gel and electroblotted onto a polyvinylidene di£uoride
¢lter (Immobilon-P, Millipore). Staining of the ¢lter with 0.25% Coo-
massie blue showed three clear bands corresponding to the molecular
weights of 150, 130 and 85 kDa. These bands were cut out using a
scalpel and loaded into an automated gas-phase protein sequencer
(Applied Biosystems model 477A) with a phenylthiohydantoin ana-
lyzer.
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2.3. Puri¢cation and subfractionation of liver mitochondria
The mitochondria were puri¢ed and subfractionated from human
liver by minor modi¢cations of a method described by Schnaitman
and Greenawalt [20]. Brie£y, liver tissue (250 g) was homogenized in
ice-cold 10 mM potassium phosphate/0.3 M sucrose/1 mM EDTA/0.5
mM DTT bu¡er (pH 7.4) by mincing with scissors and by 5 strokes in
a loose-¢tting Potter-Elvehjem homogenizer. The homogenate was
centrifuged at 1000Ug for 10 min to pellet the nuclei and residual
tissue. The supernatant was centrifuged twice at 10 000Ug for 10 min
to pellet the mitochondria with intermediate washing with one pellet
volume of homogenization bu¡er. The pellet was resuspended to a
protein concentration of approximately 100 mg/ml in the same bu¡er.
The suspension was incubated with digitonin (1.2 mg/10 mg pro-
tein) for 15 min on ice with stirring to lyse the mitochondrial outer
membranes, diluted 1:4 with homogenization bu¡er, and centrifuged
for 10 min at 15 000Ug to pellet the mitoplasts (inner membrane+
matrix). The supernatant was further centrifuged for 20 min at
144 000Ug to pellet the outer membranes. This second supernatant
contains the intermembrane proteins. The mitoplasts were treated
with lubrol (0.16 mg/mg of mitoplasts) for 10 min on ice with stirring,
diluted 1:4 with homogenization bu¡er and centrifuged at 144 000Ug
for 50 min to pellet the inner membranes. This supernatant contains
the mitochondrial matrix proteins. Each subfraction was adjusted to
3 mg protein/ml with the homogenization bu¡er and measured for
marker enzymes as follows: monoamine oxidase for the outer mem-
brane proteins [21], sul¢te oxidase for the intermembrane space [22],
succinate dehydrogenase for the inner membrane [23] and malate de-
hydrogenase for the matrix proteins [24].
To exclude lysosomal proteins, which represent a substantial frac-
tion of total proteolytic activity in these preparations [25], in control
experiments the initial mitochondrial pellet was treated with a low
concentration of digitonin (5 Wg/mg protein for 20 min at 0‡C) prior
to lysis of the outer membranes [26]. After centrifugation (10 000Ug
for 10 min) and washing, the mitochondria were subfractionated, and
the lysosomal marker enzyme acid phosphatase was measured in all
fractions according to Stevens and Thomas [27].
2.4. Proteolysis assay
Full length recombinant human XDH was expressed in COS-1 cells
as described [28]. 100 000Ug supernatants (S100) from these cell ly-
sates were incubated with samples of human liver, and the proteolysis
of XDH was revealed by denaturing polyacrylamide gel electropho-
resis followed by Western blotting using polyclonal XDH antiserum
as described [28].
The protease inhibitors were from Boehringer Mannheim, except
for phenylmethylsulfonyl £uoride (PMSF) from Sigma, N-carboben-
zoxy-Leu-Leu-Tyr-diazomethyl ketone (N-CBZ-LLY-ZMK) from
Molecular Probes, acetyl-Tyr-Val-Ala-Asp-chloromethylketone (Ac-
YVAD-CMK) and acetyl-Asp-Glu-Val-Asp-CHO (Ac-DEVD-CHO)
from Bachem, and N-benzyloxycarbonyl-Val-Ala-Asp-£uoromethyl-
ketone (Z-VAD-FMK) from Enzyme System Products. The concen-
trations used were as follows: antipain 74 WM; bestatin 130 WM;
chymostatin 33 WM; E-64 5.6 WM; leupeptin 2 WM; pepstatin
1 WM; phosphoramidon 360 WM; Pefabloc SC 1.6 mM; EDTA
1 mM; aprotinin 150 WM; calpain inhibitor I 44 WM; N-CBZ-LLY-
ZMK 50 WM; Ac-DEVD-CHO, Ac-YVAD-CMK and Z-VAD-FMK
100 WM; PMSF 1 mM.
2.5. XDH and XO activity measurements
Xanthine dehydrogenase/oxidase activities were measured by a ra-
diochemical assay described earlier [28]. Brie£y, the samples were in-
cubated for 60 min in the presence of labelled substrate (45 WM
[14C]xanthine, Amersham, speci¢c activity 50^60 mCi/mmol) in 50
mM potassium phosphate bu¡er pH 7.8 containing 0.5 mM DTT
and 1.0 mM EDTA. Total XDH+XO activity was measured in the
presence of 0.5 mM NAD in the reaction mixture, and xanthine
oxidase activity in parallel reactions without NAD. The uric acid
produced was separated from xanthine by HPLC and quanti¢ed by a
£ow-cell scintillation counter. The results (mean þ S.D. from triplicate
experiments) are expressed as a percentage of xanthine oxidase activ-
ity of total XDH+XO activity.
3. Results
SDS-PAGE analysis of puri¢ed xanthine oxidase from hu-
man milk and freeze-thawed human liver revealed that in both
sources the 150 kDa polypeptide was processed into a frag-
ment of 130 kDa and further to 85 kDa. By sequencing the
amino-terminus of the 130 kDa peptide, the primary cleavage
was determined to occur between amino acids Gln183 and
Lys184. No N-terminal sequence could be obtained from the
85 kDa peptide.
In contrast to freeze-thawed liver, cytoplasmic fractions
from fresh human liver showed an intact XDH peptide with
no signs of proteolysis when incubated for up to 1 h at 37‡C
(Fig. 1). Accordingly, the enzymatic activity was predomi-
nantly in the dehydrogenase form (Table 2).
Warm ischemia was simulated by further incubating fresh
9100 mg tissue pieces at 37‡C, and as in supernatants freshly
prepared from unfrozen liver, no signs of XDH proteolysis
were seen in the cytoplasmic fractions from these experiments.
Strikingly, one freeze-thaw cycle of the tissue pieces prior to
incubation at 37‡C resulted in rapid progression of XDH
proteolysis that could already be observed at 15 min (Fig. 1).
The fact that the cytoplasmic compartment from fresh hu-
man liver contained no XDH-XO proteolytic activity led us to
examine the insoluble fraction of the homogenate, speci¢cally
the mitochondria. Following subfractionation, the marker en-
zyme distribution of each of these subfractions is shown in
Table 1.
FEBS 21429 25-1-99
Fig. 1. XDH proteolysis in human liver preparations. Samples from
human liver were incubated: (C) as cytosol from unfrozen tissue,
(P) as fresh tissue pieces under bu¡er, and (F/T) as freeze-thawed
tissue pieces. After incubation at 37‡C for the indicated times, the
cytosolic fractions from P and F/T were extracted, and all samples
(50 Wg protein/lane) were analyzed by Western blotting using rabbit
XDH antiserum. The arrows indicate the 150, 130 and 85 kDa pep-
tides.
Table 1
Marker enzyme activity distribution (submitochondrial localization in parentheses) in the preparations of mitochondrial subfractions
Enzyme Relative activity (% of total mitochondrial activity)
M IM IMS OM
Malate dehydrogenase (M) 67 1 29 2
Succinate dehydrogenase (IM) 14 59 7 20
Sul¢te oxidase (IMS) 0 0 96 4
Monoamine oxidase (OM) 0 0 40 60
M = matrix, IM = inner membrane, IMS = intermembrane space, OM = outer membrane.
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By coincubating subfractions of the mitochondria with re-
combinant human XDH, the XDH-XO proteolytic activity
was found to be speci¢cally localized in the mitochondrial
intermembrane space (Fig. 2). The activity was soluble and
could be inactivated by heating (80‡C for 10 min). Experi-
ments with a number of antiproteases including inhibitors of
serine proteases, cysteine proteases, aspartic proteases, metal-
loproteases, calpains and caspases showed that the XDH-XO
converting activity does not belong to any of these types of
proteinolytic enzymes (Fig. 3).
When the cytoplasmic fraction of human liver was coincu-
bated with IMS proteins in the absence of DTT, the propor-
tion of XO increased ca. sevenfold (Table 2). This was mainly
due to reversible XDH-XO conversion. In the presence of 0.5
mM DTT, reversible conversion was greatly decreased, and
IMS proteins caused an approximately twofold increase in the
proportion of XO.
The lysosomal marker enzyme acid phosphatase activity
was restricted (s 90%) to the cytoplasmic preparation and
the supernatant from the low-digitonin wash. Removal of
lysosomal proteins by these procedures did not decrease the
XDH-XO proteolytic activity of the IMS subfraction of the
mitochondrial preparations (data not shown).
4. Discussion
In this study we have shown that the cytoplasmic xanthine
dehydrogenase of human liver is irreversibly cleaved to xan-
thine oxidase by a mitochondrial protease. This ¢nding is in
accordance with an early report by Stirpe and Della Corte
which suggests that a ‘xanthine oxidase activating factor’ re-
sides in cellular compartments other than the cytosol [9].
However, since these preliminary experiments the proteolytic
activity has eluded further localization and characterization.
Our data support the notion [5,6] that irreversible conver-
sion of XDH to XO occurs more readily if the enzyme is ¢rst
converted into reversible oxidase in the absence of DTT (Ta-
ble 2).
The proteolytic conversion occurs by cleavage of the poly-
peptide chain at position Gln183-Lys184 and subsequently at a
site downstream, yielding a major cleavage product of ap-
proximately 85 kDa. This is in agreement with earlier ¢ndings
for the rat XDH in in vitro experiments by digestion with
trypsin [11].
Reoxygenation of previously anoxic cells has been shown to
lead to loss of the mitochondrial membrane potential, fol-
lowed by uncoupling of oxidative phosphorylation, swelling,
and eventual lysis of the mitochondria. Thus mitochondrial
proteins are released into the cytoplasm [29]. The loss of mem-
brane potential, also called the mitochondrial permeability
transition (MPT), has been shown to occur at the early stages
of apoptosis as well as necrosis [30^32].
The di¡erent intracellular localization of XDH-XO convert-
ing proteolytic activity and the intact XDH peptide also sug-
gests that proteolytic modi¢cation of XDH to XO is mainly
triggered by reperfusion of ischemic tissue and not by the
ischemia itself, as previously speculated [33]. It is possible
that the protease has (a) physiological substrate(s) in the mi-
tochondrial intermembrane space and that it only exerts its
action on XDH in conditions preceding cell death. The rate of
proteolytic XDH to XO conversion during ischemia without
reperfusion has been shown to be relatively slow in this study
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Fig. 2. Degradation of recombinant XDH by mitochondrial inter-
membrane space proteins. Western blots of COS cell S100 superna-
tants (1 Wg protein) treated at 37‡C with speci¢c mitochondrial sub-
fractions (30 Wg total protein). Six left lanes: Time course of XDH
degradation when incubated either alone or with intermembrane
space proteins (IMS). Right lanes: Degradation of XDH when incu-
bated for 120 min with mitochondrial outer membrane proteins
(OM), inner membrane proteins (IM), matrix proteins (M) or with
the indicated combinations. Arrows as in Fig. 1.
Fig. 3. E¡ect of various protease inhibitors on XDH proteolysis.
Recombinant XDH was incubated with mitochondrial intermem-
brane space (IMS) proteins for in the presence of the indicated pro-
tease inhibitors (see Section 2 for abbreviations and concentrations).
The right lanes show heat inactivation (H.I.) of the proteolytic ac-
tivity, and XDH and IMS proteins incubated separately. Incubation
conditions as in Fig. 2.
Table 2
The e¡ect of mitochondrial intermembrane space (IMS) proteins on the proportion of xanthine oxidase activity of total XDH+XO activity in
the cytoplasm of human liver
Xanthine oxidase (%) of total XDH+XO activity
Cytoplasm (0 min) Cytoplasm (120 min) Cytoplasm+IMS proteins (120 min)
3DTT 8.6 þ 0.2 30.4 þ 0.9 56.5 þ 1.7
+0.5 mM DTT 7.0 þ 0.2 11.9 þ 0.6 17.8 þ 1.0
The incubations were carried out at 37‡C with and without dithiothreitol (DTT) to assess the contribution of the reversible and irreversible forms of
xanthine oxidase.
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and in previous reports [7,34]. The fall of intracellular pH
associated with ischemia has been shown to be cytoprotective
[35^37], supposedly by inhibition of the MPT [38,39].
As the XDH-XO converting protease activity is not inhib-
ited by Z-VAD-FMK, it appears to be distinct from the
‘apoptosis-inducing factor’ (AIF), a so far largely uncharac-
terized proapoptotic 50 kDa protein from the mitochondrial
intermembrane space with presumable proteolytic activity
[30]. Similarly, a proteolytic activity recently characterized
from rat liver mitochondrial intermembrane space was inhib-
ited by leupeptin and E-64, which had no e¡ect in our experi-
ments [40].
Intracellular calcium in£ux and subsequent mitochondrial
Ca2 overload during and after ischemia have been shown to
promote the MPT [41]. The role of excess intracellular calci-
um on XDH-XO conversion is thus likely to be indirect,
rather than directly coupled to the activation mechanism of
the protease. This would explain the lack of e¡ect of metal
chelators and calpain inhibitors on XDH-XO conversion in a
cell-free system, shown in this study. The reported inhibitory
e¡ect of the calmodulin inhibitor tri£uoperazine on the con-
version [17] could be also explained by the known ability of
tri£uoperazine to prevent the MPT [29].
Our ¢ndings also demonstrate that if the integrity of the
mitochondria is ensured during homogenization of the tissue,
almost all XDH-XO activity can be preserved in the dehydro-
genase form. The possibility that even the residual oxidase
activity is an artefact due to tissue preparation cannot be
ruled out. In contrast, in freeze-thawed tissues, in which the
integrity of biological membranes and cellular organelles, in-
cluding the mitochondria, has been a¡ected, the rate of con-
version is signi¢cantly enhanced. We postulate that this is a
consequence of a leak of mitochondrial proteins into the cy-
toplasm and ensuing XDH proteolysis. Thus isolation of the
cytoplasm prior to freezing of tissues to be analyzed is of
crucial importance and failure to do so leads to signi¢cant
background oxidase activity. These ¢ndings could account
for the controversial reports of the proportion of oxidase in
tissues and also of the rate of XDH-XO conversion
[6,15,34,42^46].
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